Tom Hanks and Type 2 Diabetes: What He Takes and How a Regular Patient Gets the Same Access

What Tom Hanks Has Actually Said About His Diabetes

Tom Hanks has not kept his diagnosis quiet. During a 2013 appearance on Late Show with David Letterman, he told the host that his doctor had been warning him about elevated blood sugar since he was 36 years old, and that the full Type 2 diabetes diagnosis had finally arrived. "I'm part of the club," he said. That interview is the primary sourced statement from which most reporting on his condition originates.

The 2013 Letterman Disclosure

In the Letterman conversation, Hanks described years of fluctuating weight and blood sugar readings that his physicians flagged as pre-diabetic territory. He did not name specific medications during that appearance. His framing was candid and self-deprecating rather than alarming, which likely contributed to broad public awareness of how gradual the slide from pre-diabetes to T2D can be.

Pre-diabetes affects an estimated 98 million U.S. Adults, according to CDC surveillance data, and roughly 80% of those individuals are unaware of their status. Hanks's willingness to discuss the progression publicly gave that statistic a recognizable face.

Subsequent Interviews and Context

In a 2016 interview on Radio Times, Hanks elaborated that weight management remained central to his approach. He acknowledged that physicians had told him for years that losing weight could normalize his blood sugar, and that he had not always followed through. He stopped short of describing a specific drug regimen, which is consistent with most celebrity health disclosures.

Any specific medication Hanks may currently use is not publicly confirmed. What follows is a clinical description of the standard-of-care treatment ladder that any board-certified endocrinologist or internist would apply to a patient with his profile. Where inference is used, it is labeled as such.

The Standard Treatment Ladder for Type 2 Diabetes

The American Diabetes Association's Standards of Medical Care in Diabetes 2024 organizes T2D pharmacotherapy into a clear sequence based on A1C, cardiovascular risk, kidney function, and body weight. The full guideline is available through Diabetes Care. A patient with Hanks's publicly described history, longstanding elevated blood sugar, fluctuating weight, and now-confirmed T2D diagnosis, would likely have moved through at least the first two tiers of this ladder.

Tier 1: Metformin

Metformin is the starting drug for most newly diagnosed T2D patients who tolerate it. It works by reducing hepatic glucose output and improving peripheral insulin sensitivity. Typical dosing starts at 500 mg once or twice daily with meals and titrates to 1,000 to 2,000 mg/day over four to eight weeks.

A 2012 Cochrane review of metformin vs. Placebo and active comparators confirmed that metformin reduces A1C by approximately 1 to 1.5 percentage points as monotherapy, with a low hypoglycemia risk and a favorable cardiovascular signal in the UKPDS 34 sub-study (UKPDS Group, Lancet 1998). The ADA continues to list it as preferred initial pharmacotherapy for most adults unless contraindicated by eGFR <30 mL/min/1.73 m² or gastrointestinal intolerance.

Tier 2: GLP-1 Receptor Agonists

When metformin alone does not achieve an A1C below 7%, or when a patient carries significant cardiovascular or weight-related risk, guidelines recommend adding a GLP-1 receptor agonist (GLP-1 RA). This class includes semaglutide (Ozempic, Rybelsus), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro), which acts on both GLP-1 and GIP receptors.

The cardiovascular outcome trial SUSTAIN-6 (N=3,297) demonstrated that subcutaneous semaglutide 0.5 mg or 1.0 mg weekly reduced the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke by 26% compared to placebo over 104 weeks (HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for non-inferiority; P=0.02 for superiority) (Marso et al., NEJM 2016). This cardiovascular benefit is independent of glucose lowering.

For patients with T2D who also carry excess weight, the STEP-2 trial (N=1,210) tested semaglutide 2.4 mg weekly and showed a mean weight reduction of 9.6% vs. 3.4% placebo at 68 weeks (Wilding et al., NEJM 2021, STEP-1 cohort data). Given Hanks's public discussion of weight as a key variable in his blood sugar control, a GLP-1 RA would be a clinically logical addition to his regimen. This is inference based on guideline-directed care for his disclosed profile, not confirmed reporting.

Tier 3: Basal Insulin

When A1C remains above target despite two or more oral or injectable agents, basal insulin is added. Options include insulin glargine U-100 (Lantus, Basaglar), insulin degludec (Tresiba), and insulin glargine U-300 (Toujeo). Starting doses are typically 10 units subcutaneously at bedtime, titrated by 2 units every three days until fasting glucose reaches 80 to 130 mg/dL, per the ADA 2024 titration algorithm (ADA Standards of Care 2024).

Hanks has never publicly confirmed insulin use. His framing in interviews suggests ongoing management that responds to lifestyle input, which is more consistent with oral or GLP-1 therapy than with insulin dependence. That remains inference.

Tirzepatide: The Newest Option With the Strongest Weight Data

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is a dual GIP/GLP-1 receptor agonist approved by the FDA in May 2022 for T2D and in November 2023 for chronic weight management (FDA approval record). The SURPASS-2 trial (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg weekly against semaglutide 1 mg weekly in adults with T2D. At 40 weeks, tirzepatide 15 mg produced a mean A1C reduction of 2.46 percentage points vs. 1.86 for semaglutide (P<0.001) and a mean weight loss of 11.2 kg vs. 5.7 kg (Frias et al., NEJM 2021).

The SURMOUNT-1 trial (N=2,539), conducted in adults with obesity but without T2D, found that tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks vs. 3.1% placebo (Jastreboff et al., NEJM 2022). These numbers make tirzepatide the most effective approved pharmacotherapy for combined glycemic and weight management currently on the market.

A clinician evaluating a patient with Hanks's profile in 2025 would face a genuine choice between semaglutide 1 mg weekly (established cardiovascular outcome data) and tirzepatide 10 to 15 mg weekly (superior glucose and weight endpoints, cardiovascular outcome trial SURPASS-CVOT results pending full publication). The decision hinges on individual cardiovascular history, insurance formulary, and tolerability.

How a Regular Patient Accesses These Medications

This is the section most readers are actually here for. The short answer: none of these drugs require a celebrity's resources or a concierge physician. They are covered under most commercial insurance plans and Medicare Part D, and they can be prescribed through a telehealth visit.

Step 1: Get a Confirmed Diagnosis

A diagnosis of Type 2 diabetes requires one of the following, confirmed on two separate occasions unless symptoms are present (ADA Standards of Care 2024):

• Fasting plasma glucose ≥126 mg/dL
• 2-hour plasma glucose ≥200 mg/dL during a 75 g oral glucose tolerance test
• A1C ≥6.5%
• Random plasma glucose ≥200 mg/dL with classic hyperglycemia symptoms

A primary care physician, internist, or endocrinologist can order these labs. Many telehealth platforms now include at-home lab kit coordination, meaning a patient can complete the diagnostic workup without leaving the house.

Step 2: Establish Care With a Prescribing Clinician

Board-certified physicians can prescribe metformin, GLP-1 receptor agonists, and insulin via telehealth in most U.S. States under current prescribing law. A standard initial visit covers medical history, current A1C, kidney function (to check eGFR before metformin), cardiovascular risk factors, and medication preference.

The ADA guideline states: "For patients with T2D and established cardiovascular disease, heart failure, or chronic kidney disease, a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit is recommended independent of baseline A1C or individualized A1C target." This means a clinician can start a GLP-1 RA as the first injectable agent without requiring metformin failure first, if cardiovascular risk is high enough (ADA Standards of Care 2024, Section 9).

Step 3: Understand Insurance and Cost

Semaglutide 1 mg weekly (Ozempic) carries a list price above $900/month without insurance, but most commercial plans and Medicare Part D formularies cover it for confirmed T2D with a prior authorization form. Novo Nordisk's patient assistance program (NovoCare) provides Ozempic at no cost to patients earning <400% of the federal poverty level who lack insurance coverage.

Tirzepatide (Mounjaro) follows a similar structure through Eli Lilly's Lilly Cares program. Metformin generic costs $4, $10/month at most retail pharmacies regardless of insurance.

Step 4: Monitor and Titrate

After starting therapy, A1C should be rechecked at three months. The ADA recommends quarterly A1C testing until the target of <7% is stable, then every six months (ADA Standards of Care 2024). Continuous glucose monitors (CGMs) such as the Dexterity G7 or FreeStyle Libre 3 are now covered under Medicare for all insulin-using T2D patients, and commercial coverage is expanding rapidly following 2023 CMS guidance.

Lifestyle: The Piece Hanks Has Spoken About Most

Hanks has repeatedly credited dietary changes and weight management as central to his T2D control. That aligns precisely with the evidence. The Look AHEAD trial (N=5,145, 9.6-year follow-up) tested an intensive lifestyle intervention (ILI) targeting ≥7% weight loss through caloric restriction and ≥175 min/week of physical activity against a diabetes support and education control. ILI participants lost a mean of 6.0% of initial weight at year one vs. 0.9% in the control group, with significantly greater A1C reductions at one year (mean difference 0.36 percentage points) (Wing et al., NEJM 2013).

Cardiovascular event rates did not differ significantly between groups at the trial's primary endpoint, but ILI participants showed superior fitness, lower rates of depression, and better quality-of-life scores across the follow-up period. Weight loss of 5 to 10% reliably improves fasting glucose, A1C, blood pressure, and triglycerides in T2D, and these improvements are additive to pharmacotherapy rather than alternatives to it.

The practical advice from the ADA Nutrition Consensus Report (2019) is to reduce total caloric intake, prioritize non-starchy vegetables, lean proteins, and minimally processed whole grains, and limit refined carbohydrates and sugar-sweetened beverages (Evert et al., Diabetes Care 2019). No single named diet pattern (Mediterranean, low-carb, DASH) was superior across all outcomes, though all performed better than unrestricted eating.

SGLT2 Inhibitors: A Fourth Pillar Worth Knowing

One class not yet mentioned is SGLT2 inhibitors: empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana). These drugs block glucose reabsorption in the proximal renal tubule, causing urinary glucose excretion of roughly 60 to 80 g/day and producing modest A1C reductions of 0.5 to 1.0 percentage points as add-on therapy.

Their clinical importance lies in organ protection. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% (HR 0.62, 95% CI 0.49 to 0.77, P<0.001) and hospitalization for heart failure by 35% vs. Placebo in T2D patients with established cardiovascular disease (Zinman et al., NEJM 2015). The CREDENCE trial demonstrated canagliflozin's renal protective effects in T2D patients with diabetic kidney disease, reducing the composite renal endpoint by 30% (Perkovic et al., NEJM 2019).

A patient with T2D and either heart failure or early chronic kidney disease (eGFR 30 to 60) may receive an SGLT2 inhibitor as a first injectable-free add-on to metformin, before or alongside a GLP-1 RA.

Putting It Together: A Realistic 2025 Treatment Plan for a Patient Like Tom Hanks

A 68-year-old male with a 12-year history of Type 2 diabetes, fluctuating weight, and no publicly confirmed cardiovascular events would most likely be managed on the following regimen by a 2025-standard-of-care internist or endocrinologist:

• Metformin 1,000 mg twice daily with meals (assuming eGFR ≥45)
• Semaglutide 1 mg subcutaneously weekly (or tirzepatide 10 to 15 mg weekly if metformin alone is insufficient and weight reduction is a priority)
• An SGLT2 inhibitor if A1C remains above target and renal function supports it
• Dietary pattern aligned with ADA Nutrition Consensus recommendations
• A1C rechecked every three months until stable at <7%

This is not a novel regimen. A board-certified physician at a telehealth platform reviews the same evidence and applies the same ADA guidelines. The prescription pad available to a Hollywood actor is the same one available to a postal worker in Omaha.

Access is primarily a function of having a confirmed diagnosis, a prescribing clinician, and (for the more expensive agents) an insurance card or a manufacturer assistance program enrollment form.